Keyword :   non-small cell lung cancer

From theory to practice. The art of lung cancer treatment
Т. 14, №3 (55)
Efficacy of EGFR TKIs of different generations in NSCLC with EGFR mutations: review of clinical studies and our experience
Authors: Kobziev O.I. Boiarskyi O.O. Leonova V.V. Т. 12, № 3-4 (47-48)
Pembrolizumab is first-line treatment for patients with advanced non-small cell lung cancer in both mono and combination regimens
T. 10, № 1-2 (37-38)
Prevalence of EGFR gene mutations in Ukrainian patients with locally advanced or metastatic non-small cell lung cancer
Authors: Shparyk Ya.V. Ponomareva O.V. Sokolov V.V. Kobzev O.Y.... T. 10, № 1-2 (37-38)
ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 4 (32) 2018
The role of targeted therapy in the treatment of patients with EGFR+ mutations of lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 3 (31) 2018
Modern approaches to the treatment of inoperable non-small cell lung cancer
Authors: Klimаnоv М.Yu. Sivak L.A. Tarasenko T. Askоlskiy А.В.... №4(24) 2016
Erlotinib efficacy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Author:Toracica Oncologia Italiana Associazione and Pneumo-Cancerologie de Francais Groupe with collaboration in Group Cancer Lung Spanish №7 (3) 2012
Expression of glicoprotein Pgp-170 by the hemopoietic peripheral blood and bone marrow cells in the CML patients with different response to tyrosine kinase inhibitors therapy
Authors: Perekhrestenko T.P. Gordiyenko A.I. Tretyak N.N. Dyagil I.S.... №5 (1) 2012